Compare IBRX & TFPM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBRX | TFPM |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Precious Metals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.8B |
| IPO Year | 2015 | 2022 |
| Metric | IBRX | TFPM |
|---|---|---|
| Price | $7.54 | $29.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | $12.57 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 12.2M | 703.3K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 0.72% |
| EPS Growth | ★ 38.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $113,288,000.00 | N/A |
| Revenue This Year | $88.59 | $29.19 |
| Revenue Next Year | $131.15 | N/A |
| P/E Ratio | ★ N/A | $35.57 |
| Revenue Growth | ★ 668.31 | N/A |
| 52 Week Low | $1.95 | $22.60 |
| 52 Week High | $12.43 | $41.70 |
| Indicator | IBRX | TFPM |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 51.39 |
| Support Level | $6.69 | $26.89 |
| Resistance Level | $8.54 | $32.16 |
| Average True Range (ATR) | 0.54 | 0.91 |
| MACD | -0.12 | 0.08 |
| Stochastic Oscillator | 12.61 | 47.58 |
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Triple Flag Precious Metals Corp is a streaming and royalty company focused on precious metals. Its revenues are largely generated from a diversified portfolio of properties in Australia, Canada, Colombia, Cote d'Ivoire, Mexico, Mongolia, Peru, South Africa, and the United States. Its diversified portfolio of streams and royalties comprises long-life mining assets, including the Northparkes copper-gold mine in Australia, the Cerro Lindo polymetallic mine in Peru, the Fosterville gold mine in Australia, the Buritica gold mine in Colombia, and the Impala Bafokeng Operations in South Africa among others. A majority of its revenue is derived through its interests in various gold streams. Geographically, the company derives maximum revenue from Australia, followed by Peru and other regions.